Follow-The-Filings

Security · featured owners

CYTK Cytokinetics Inc.

Health Care COM NEW Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 2.8%
  • $18M
  • 2 reduce

CYTK (Cytokinetics Inc.) is held in 3 featured 13F books as of 2026 Q2. Nathan Fischel - Dafna Capital Management is the largest tracked holder by portfolio weight (2.8%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 2.8% (Nathan Fischel - Dafna Capital Management) · not free-float ownership

  1. Nathan Fischel reduce 2.8%
  2. Palo Alto Investors 0.38%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Nathan Fischel - Dafna Capital Management 2026 Q2 2.8% Reduce −20.9% 171,998 $15M history
Palo Alto Investors 2026 Q2 0.38% Hold 32,195 $3M history
Ron Baron - Bamco Inc. (Baron Capital) 2026 Q2 <0.01% Reduce −56.5% 10,000 $852K history

3 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 4 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 17 rows shown

Filed Form Detail Links
4 Period Sep 11, 2026 Filing Doc
4 Period Sep 8, 2026 Filing Doc
4 Period Sep 1, 2026 Filing Doc
4 Period Aug 31, 2026 · 2 forms Filing Doc
4 Period Aug 18, 2026 Filing Doc
4 Period Aug 10, 2026 Filing Doc
4 Period Jul 30, 2026 Filing Doc
4 Period Jul 27, 2026 Filing Doc
4 Period Jul 21, 2026 Filing Doc
4 Period Jul 15, 2026 · 6 forms Filing Doc
4 Period Jul 13, 2026 Filing Doc
4 Period Jul 7, 2026 Filing Doc
4 Period Jul 1, 2026 · 3 forms Filing Doc
4 Period Jun 29, 2026 Filing Doc
4 Period Jun 24, 2026 Filing Doc
4 Period Jun 23, 2026 Filing Doc
4 Period Jun 15, 2026 Filing Doc

Updated 4 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $7.53M $18.47M $88.04M
Net income -$526.24M -$589.53M -$784.96M
Net margin * -6988.6% -3191.1% -891.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.628B $1.11B $0.917B
Total non-current assets * $196.26M $293.73M $507.56M
Total assets $0.824B $1.4B $1.42B
Total current liabilities $102.68M $179.67M $202.45M
Total non-current liabilities * $1.11B $1.36B $1.88B
Total equity -$386.32M -$135.37M -$659.62M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$414.33M -$395.89M -$510.01M
Cash from investing $239.25M -$553.1M $16.67M
Cash from financing $221.32M $930.61M $524.46M
Net change in cash $46.22M -$18.17M $30.4M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders